Seelaus Asset Management LLC Has $531,000 Position in CVS Health Co. (NYSE:CVS)

Seelaus Asset Management LLC reduced its stake in CVS Health Co. (NYSE:CVS) by 5.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,730 shares of the pharmacy operator’s stock after selling 405 shares during the period. Seelaus Asset Management LLC’s holdings in CVS Health were worth $531,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Weik Capital Management grew its stake in CVS Health by 0.7% in the first quarter. Weik Capital Management now owns 17,600 shares of the pharmacy operator’s stock valued at $1,781,000 after acquiring an additional 120 shares during the period. FCA Corp TX grew its position in CVS Health by 0.6% in the 1st quarter. FCA Corp TX now owns 20,109 shares of the pharmacy operator’s stock valued at $2,035,000 after purchasing an additional 122 shares during the period. Arvest Trust Co. N A increased its stake in CVS Health by 1.2% during the 4th quarter. Arvest Trust Co. N A now owns 11,157 shares of the pharmacy operator’s stock valued at $1,040,000 after purchasing an additional 131 shares in the last quarter. SOA Wealth Advisors LLC. raised its holdings in CVS Health by 4.9% during the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after buying an additional 133 shares during the last quarter. Finally, Apella Capital LLC lifted its stake in shares of CVS Health by 4.2% in the fourth quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock valued at $272,000 after buying an additional 136 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now directly owns 39,765 shares in the company, valued at approximately $3,059,916.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.25% of the company’s stock.

CVS Health Trading Down 2.0 %

Shares of CVS stock opened at $69.74 on Friday. CVS Health Co. has a 12-month low of $64.41 and a 12-month high of $83.25. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77. The company has a 50 day moving average of $75.94 and a 200-day moving average of $73.77. The firm has a market cap of $87.91 billion, a P/E ratio of 10.80, a PEG ratio of 0.94 and a beta of 0.52.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.11. The firm had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.99 earnings per share. Sell-side analysts anticipate that CVS Health Co. will post 8.33 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 3.81%. CVS Health’s dividend payout ratio is presently 41.18%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company lowered their target price on shares of CVS Health from $83.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday. HSBC began coverage on CVS Health in a research note on Friday, December 22nd. They issued a “buy” rating and a $94.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $87.00 target price on shares of CVS Health in a research report on Wednesday. Piper Sandler increased their price target on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Finally, Barclays began coverage on shares of CVS Health in a report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective on the stock. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.